Retrievable, temporary IVC filters began to appear on the market in the early 2000s. They were specifically designed to have a less secure implantation to facilitate retrieval. In 1999, the US Food and Drug Administration (FDA) downgraded the risk of IVC filters from class III to class II, thereby permitting manufacturers to achieve market approval more readily under the assumption that new filters are substantially equivalent to other legally marketed devices. As a consequence, several retrievable IVC filters were submitted to the FDA and approved as permanent filters with an option for retrieval. However, there have since been multiple reports demonstrating significant complications, including vena caval penetration, filter embolization, recurrent VTE, and caval thrombosis. In 2010, the FDA disclosed that retrievable IVC filters had been associated with more than 900 adverse events; therefore, in 2014, the FDA released updated recommendations in which physicians were advised to remove filters within 25 to 54 days of their implantation. Little evidence exists to show that this recommendation is followed routinely.